Licensing-out of a sensorineural hearing loss compound to Otonomy and termination of the agreement

An individual partnering theme in which Kyorin Pharmaceutical licensed the worldwide exclusive rights to a compound for sensorineural hearing loss to US-based Otonomy, setting an upfront payment, development and sales milestones, and royalties, before the agreement was terminated.